Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1212584

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1212584

Anemia Drugs

PUBLISHED:
PAGES: 383 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5450
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16350

Add to Cart

Description

Table of Contents

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Anemia Drugs Market to Reach $16.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Anemia Drugs estimated at US$12.3 Billion in the year 2022, is projected to reach a revised size of US$16.9 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2022-2030. Iron Deficiency Anemia, one of the segments analyzed in the report, is projected to record a 5.1% CAGR and reach US$7.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Sickle Cell Anemia segment is readjusted to a revised 4.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $3.3 Billion, While China is Forecast to Grow at 7% CAGR

The Anemia Drugs market in the U.S. is estimated at US$3.3 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 3.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.2 Billion by the year 2030.

Select Competitors (Total 51 Featured):

  • Acceleron Pharma, Inc.
  • Amgen, Inc.
  • Bayer AG
  • Biocon Ltd.
  • bluebird bio, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • GlycoMimetics, Inc.
  • Regen Biopharma Inc.
Show more
Product Code: MCP-6192

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Anemia Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Anemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Anemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 3: World 18-Year Perspective for Anemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Iron Deficiency Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Iron Deficiency Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 6: World 18-Year Perspective for Iron Deficiency Anemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Sickle Cell Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Sickle Cell Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 9: World 18-Year Perspective for Sickle Cell Anemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Aplastic Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Aplastic Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 12: World 18-Year Perspective for Aplastic Anemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Hemolytic Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Hemolytic Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 15: World 18-Year Perspective for Hemolytic Anemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pernicious Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Pernicious Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 18: World 18-Year Perspective for Pernicious Anemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 21: World 18-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 22: World Anemia Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 25: USA 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 28: Canada 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • JAPAN
    • Anemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 31: Japan 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • CHINA
    • Anemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 34: China 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • EUROPE
    • Anemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Anemia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Anemia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 37: Europe 18-Year Perspective for Anemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 40: Europe 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • FRANCE
    • Anemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 43: France 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • GERMANY
    • Anemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 46: Germany 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 49: Italy 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • UNITED KINGDOM
    • Anemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 52: UK 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • SPAIN
    • TABLE 53: Spain Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Spain Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 55: Spain 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Russia Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 58: Russia 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • REST OF EUROPE
    • TABLE 59: Rest of Europe Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Rest of Europe Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 61: Rest of Europe 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • ASIA-PACIFIC
    • Anemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Anemia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Anemia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 64: Asia-Pacific 18-Year Perspective for Anemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 67: Asia-Pacific 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • AUSTRALIA
    • Anemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 68: Australia Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Australia Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 70: Australia 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • INDIA
    • Anemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 71: India Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: India Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 73: India 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • SOUTH KOREA
    • TABLE 74: South Korea Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: South Korea Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 76: South Korea 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 77: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Rest of Asia-Pacific Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 79: Rest of Asia-Pacific 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • LATIN AMERICA
    • Anemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Anemia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Anemia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 82: Latin America 18-Year Perspective for Anemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2023 & 2030
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 85: Latin America 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • ARGENTINA
    • TABLE 86: Argentina Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Argentina Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 88: Argentina 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • BRAZIL
    • TABLE 89: Brazil Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Brazil Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 91: Brazil 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • MEXICO
    • TABLE 92: Mexico Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Mexico Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 94: Mexico 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 95: Rest of Latin America Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Rest of Latin America Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 97: Rest of Latin America 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • MIDDLE EAST
    • Anemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Anemia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Anemia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 100: Middle East 18-Year Perspective for Anemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2023 & 2030
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 103: Middle East 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • IRAN
    • TABLE 104: Iran Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Iran Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 106: Iran 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • ISRAEL
    • TABLE 107: Israel Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Israel Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 109: Israel 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 110: Saudi Arabia Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Saudi Arabia Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 112: Saudi Arabia 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 113: UAE Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: UAE Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 115: UAE 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 116: Rest of Middle East Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Rest of Middle East Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 118: Rest of Middle East 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030
  • AFRICA
    • Anemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 119: Africa Recent Past, Current & Future Analysis for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Africa Historic Review for Anemia Drugs by Type - Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 121: Africa 18-Year Perspective for Anemia Drugs by Type - Percentage Breakdown of Value Sales for Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia and Other Types for the Years 2012, 2023 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!